Trimethylamine N-oxide (TMAO) is a biologically active gut microbiome-derived dietary
metabolite. Recent studies have shown that high circulating plasma TMAO levels are closely …

The gut microbiome is defined as an ecological community of commensal symbiotic and
pathogenic microorganisms that exist in our body. Gut microbiome dysbiosis is a condition of …

Baihu Rensheng decoction (BHRS) can effectively improve insulin resistance (IR) and
decrease blood glucose in diabetic patients. However, its specific mechanism of action …

Prediabetes and colorectal cancer (CRC) represent compelling health burdens responsible
for high mortality and morbidity rates, sharing several modifiable risk factors. It has been …

The intestinal microbiota refers to the collection of microorganisms that exist in the human
gut. It has been said that bacteria influence the development of metabolic diseases, such as …

Human gut microbiota are recognized as critical players in both metabolic disease and drug
metabolism. However, medication–microbiota interactions in cardiometabolic diseases are …

Background Sulfonylureas have been a longstanding pharmacotherapy in the management
of type 2 diabetes, with potential benefits beyond glycemic control. Although sulfonylureas …

Objectives We here assessed whether typical pathogens of laboratory mice affect the
development of diet-induced obesity and glucose intolerance, and whether colonization …

Our study focused on a mouse model of obesity induced by a high-fat diet (HFD). We
administered Semaglutide intraperitoneally (Ozempic®—0.05 mg/Kg—translational dose) …

Aim The alpha-glucosidase inhibitor acarbose is approved for the treatment of type 2
diabetes (T2D). It acts in the lumen of the gut by reducing intestinal hydrolysis and …